Methimazole-Induced Febrile Neutropenia

Year 2018, Volume: 9 Issue: 1, 13 - 15, 01.01.2018

Behçet Varışlı Sinan Yıldırım Hatice Karaçam Şehnaz Paker

Abstract

Introduction: Antithyroid drugs (ATD) are commonly used for the treatment of thyrotoxicosis, particularly for the treatment of Grave’s disease. Methimazole is the first line ATD. A major fatal adverse effect of ATDs, if unrecognized and not treated on time, is agranulocytosis, which is defined as an absolute neutrophil count of <500/μL. The incidence of ATD-induced agranulocytosis is 0.1%–0.3% (1). In this study, we report on a patient who developed granulocytopenic febrile neutropenia at 3 months after treatment with methimazole (5 mg twice a day per os (BID PO)).Case report: A 51-year-old female patient presented to the emergency department with complaints of fever, fatigue, and productive cough. Her body temperature was 38.5°C; rales were heard on the mid and basal part of the left lung. Drug history revealed methimazole use (10 mg per day over the last 2 months). The WBC count was 1020/μL, and the neutrophil count was 200/μL. The patients’ baseline WBC differential count and immune status were normal. Following inpatient antibiotic treatment and discontinuation of methimazole, the patient became afebrile within 2 days. After 2 weeks of discontinuation of methimazole, we performed CBC and observed the following: WBC, 5180/μL and neutrophil count, 3280/μL.Conclusion: Patients visiting the emergency department with symptoms of a systemic infection and known to use ATDs should be thoroughly evaluated, and the possibility of drug-induced agranulocytosis developing because of the use of these medications should be considered. It is very important for emergency physicians to recognize this rare patient population and act in a timely manner

Keywords

Methimazole, febrile neutropenia, agranulocytosis, antithyroid drugs, fever, emergency medicine

References

• Melmed S, Polonsky KS, P. Larsen R, Kronenberg HM. Williams textbook of endocrinology. 13th edition. ed. Hyperthyroid Disorders, ed. T.F. Da- vies, P. Laurberg, and R.S. Bahn. 2016, Philadelphia, PA: Elsevier. xviii, 1916 pages.
• Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol 2016; 27(suppl 5): p. v111-v8. [CrossRef]
• Weetman AP. The thyroid gland and disorders of thyroid function: Oxford Textbook of Medicine. Oxford University Press; 2010: 1826-44. [CrossRef]
• Vicente N, Cardoso L, Barros L, Carrilho F. Antithyroid Drug-Induced Agranulocytosis: State of the Art on Diagnosis and Management. Drugs R D 2017; 17: 91-6. [CrossRef]
• Yang J, Zhong J, Xiao XH, Zhou LZ, Chen YJ, Liu JH, et al. The relation- ship between bone marrow characteristics and the clinical prognosis of antithyroid drug-induced agranulocytosis. Endocr J 2013; 60: 185-9. [CrossRef]
• Cheung CL, Sing CW, Tang CS, Cheng VK, Pirmohamed M, Choi CH, et al. HLA-B*38:02:01 predicts carbimazole/methimazole-induced agranulo- cytosis. Clin Pharmacol Ther 2016; 99: 555-61. [CrossRef]
• Hallberg P, Eriksson N, Ibañez L, Bondon-Guitton E, Kreutz R, Carvajal A, et al. Genetic variants associated with antithyroid drug-induced agran- ulocytosis: a genome-wide association study in a European population. Lancet Diabetes Endocrinol 2016; 4: 507-16. [CrossRef]
• Jabr FI. Methimazole-induced severe febrile neutropenia responding to recombinant human granulocyte colony stimulating factor. South Med J 2008; 101: 665. [CrossRef]